Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Black rice extract may give your brain a boost

NCT ID NCT06594848

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a supplement made from black rice extract can increase levels of BDNF, a protein important for memory and mood. Researchers will give 12 healthy adults either the supplement or a placebo and measure BDNF in their blood. The goal is to see if this natural extract can support brain health.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 12 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2024

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. The subject is healthy and, in the opinion of the investigator, free of any medical conditions that might affect study measurements. 2. Male or female. 3. Age between 18 - 80 years inclusive. 4. BMI between 21 - 29.9 kg/m2. 5. Female subject of childbearing potential has a negative urine pregnancy test result. 6. Subject agrees to discontinue the use of pre- and/or probiotic and/or polyphenol supplements from 2 days prior to the screening and throughout the study. 7. Subject agrees to consume less than 1/2 cup/day of foods containing AC (such as blueberries, blackberries, bilberries, cherries, grapes, grape juice, pomegranate, raspberries, huckleberries, strawberries) and no more than 1 glass/day of red wine, 3 cups/day of tea or coffee, or 10 g/day of dark chocolate from 2 days prior to the screening and throughout the study. 8. No known allergies to study products or components (rice). 9. Subject is willing to consume a low fat/low flavonoid dinner the evening before study visits. 10. Subject has received a complete COVID-19 vaccine and is at least 6 weeks post-vaccine at the pre-screening visit as verified by shot record or similar documentation. 11. Subject has given voluntary, written, informed consent to participate in the study. Exclusion Criteria: 1. Age \< 18 or \> 80 years. 2. BMI \< 21 or \> 29.9 kg/m2. 3. Vegan, Vegetarian, or other dietary restrictions that would not allow the subject to easily consume a low polyphenol diet leading up to screening and study visits. 4. Current consumption of special diets (e.g. Atkins, keto, paleo, etc.). 5. Current participation or enrollment in another pharmaceutical, weight-loss or nutritional clinical study within the last 30 days. Device trials are exempted. 6. Uncontrolled hypertension defined as diastolic blood pressure ≥ 95 mmHg and/or systolic blood pressure ≥ 160 mmHg. 7. Fasting blood triglycerides \> 150 mg/dL. 8. Self-reported Type 2 Diabetes. 9. Fasting blood glucose \<50 mg/dL or \> 100 mg/dL. 10. Hemoglobin A1c levels ≥ 5.7%. 11. Current smoker or use of tobacco products within the last 180 days. 12. Binge drinking (alcohol intake ≥ 5 alcoholic drinks for males or ≥ 4 alcoholic drinks for females on the same occasion, i.e. at the same time or within a couple of hours of each other). 13. Substance abuse or dependence within the last 60 days. 14. Daily use of anti-inflammatory medications including NSAIDs and aspirin within the last 30 days. 15. Use of laxative medications or other products that promote colon cleansing within the last 30 days. 16. History of restricted diets or use of herbal supplements or medications that interfere with insulin metabolism within the last 30 days. 17. History of stroke, hepatic, gallbladder, kidney, thyroid disease, or cancer. 18. History of immune related disorders or Raynaud's disease. 19. Current clinically significant depression, anxiety, or other psychiatric condition. 20. History of malabsorption or GI tract disorders. 21. History of GI surgeries (e.g. lap band, gastric bypass, etc.). 22. Diarrhea or oral antibiotic intake within the last 30 days. 23. Weight change (\> 5%) within the last 30 days. 24. History of eating disorders such as bulimia, anorexia, or muscle dysmorphia. 25. Allergy or sensitivity to the study products. 26. Subject has not received a complete COVID-19 vaccine or is less than 6 weeks post-vaccine at the screening visit. 27. Any other condition which in the Investigator's opinion might adversely affect the subject's ability to complete the study or its measurements or which might pose significant risk to the subject.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cognition - other are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Ragle Human Nutrition Research Center, Academic Surge II

    Davis, California, 95616, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.